ALISO VIEJO, Calif.,
July 8, 2019 /PRNewswire/
-- When it comes to opioid-related overdose deaths in
California, Orange County ranks among the top 20 counties
in the state with the highest rates, with 255 deaths in 2017 alone.
For Laguna Treatment Hospital, Orange
County's first chemical dependency recovery hospital, these
statistics are a call to action. The hospital was recently awarded
a $100,000 grant from the Center at
Sierra Health Foundation via the California Department of Health
Care Services to enhance its medication-assisted treatment (MAT)
services to combat the opioid crisis.
"Medication-assisted therapy is the gold standard of care for
opioid use disorder, yet in Orange
County there is a shortage of community resources that offer
this treatment once someone leaves the hospital," said Bob Hails, Laguna Treatment Hospital CEO. "We
want the community to know they can turn to us for help. This grant
will help us to do even more to support those struggling with
addiction."
As a best practice, Laguna Treatment Hospital offers
medication-assisted therapy for every level of care, from detox,
inpatient rehabilitation and residential treatment to partial
hospitalization and intensive outpatient services. With the grant,
the hospital plans to develop new MAT services, increase localized
treatment of opioid use disorder and make facility improvements to
enhance medication management and patient privacy areas.
With San Diego county within a
short driving distance, the hospital hopes to serve patients from
that community as well. The county also ranks in the top 20 for its
opioid-related overdose death rate.
"To be a part of this statewide initiative to build a growing
network of MAT services is a critical step forward in saving
lives," said Hails.
About Laguna Treatment Hospital
Laguna Treatment
Hospital is part of the American Addiction Centers' (NYSE: AAC)
family of treatment centers. AAC is a leading provider of
inpatient and outpatient substance use treatment services. We treat
adults who are struggling with drug addiction, alcohol addiction,
and co-occurring mental/behavioral health issues. We currently
operate substance abuse treatment facilities located throughout
the United States. These
facilities are focused on delivering effective clinical care and
treatment solutions. For more information, please find us at
AmericanAddictionCenters.org or call 1-800-Alcohol. You can also
follow us on Twitter @AAC_Tweet.
Forward Looking Statements
This release contains forward-looking statements within the
meaning of the federal securities laws. These forward-looking
statements are made only as of the date of this release. In some
cases, you can identify forward-looking statements by terms such as
"anticipates," "believes," "could," "estimates," "expects," "may,"
"potential," "predicts," "projects," "should," "will," "would," and
similar expressions intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements may include information
concerning AAC Holdings, Inc.'s (collectively with its
subsidiaries; "AAC Holdings" or the "Company") possible or assumed
future results of operations, including descriptions of the
Company's revenue, profitability, outlook and overall business
strategy. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results
and performance to be materially different from the information
contained in the forward-looking statements. These risks,
uncertainties and other factors include, without limitation: (i)
the Company's inability to effectively operate its facilities; (ii)
the Company's reliance on its sales and marketing program to
continuously attract and enroll clients; (iii) a reduction in
reimbursement rates by certain third-party payors for inpatient and
outpatient services and point-of-care and definitive lab testing;
(iv) the Company's failure to successfully achieve growth through
acquisitions and de novo projects; (v) risks associated with
estimates of the value of accounts receivable or deterioration in
collectability of accounts receivable; (vi) a failure to achieve
anticipated financial results from contemplated and prior
acquisitions; (vii) the possibility that a governmental entity may
prohibit, delay or refuse to grant approval for the consummation of
an acquisition; (viii) the Company's failure to achieve anticipated
financial results from contemplated and prior acquisitions; (ix) a
disruption in the Company's ability to perform diagnostic
laboratory services; (x) maintaining compliance with applicable
regulatory authorities, licensure and permits to operate the
Company's facilities and laboratories; (xi) a disruption in the
Company's business and reputational and economic risks associated
with the civil securities claims brought by shareholders or claims
by various parties; (xii) inability to meet the covenants in the
Company's loan documents or lack of borrowing capacity; and (xiii)
general economic conditions, as well as other risks discussed in
the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31,
2018 and other filings with the Securities and Exchange
Commission. As a result of these factors, we cannot assure you that
the forward-looking statements in this release will prove to be
accurate. Investors should not place undue reliance upon
forward-looking statements.
Contact: Joy Sutton,
615-727-8407, jsutton@contactaac.com
View original
content:http://www.prnewswire.com/news-releases/laguna-treatment-hospital-awarded-100-000-grant-to-combat-opioid-crisis-300880987.html
SOURCE Laguna Treatment Hospital